Orforglipron approved for obesity

The U.S. Food and Drug Administration approved Eli Lilly’s Foundayo, the brand name for orforglipron, on April 1 for adults with obesity or overweight with at least one weight-related medical problem, according to FDA and company statements. The drug is a once-daily oral GLP-1 receptor agonist, a category dominated in recent years by injectable medicines. Lilly said the pill can be taken without food or water restrictions. The approval gives the obesity market a new oral entrant as demand for GLP-1 medicines continues to expand. ### When was orforglipron actually approved, and for whom? April 1, 2026 is the approval date listed by both the FDA and Eli Lilly. The FDA’s approval letter says Foundayo is indicated, with diet and physical activity, to reduce excess body weight and maintain long-term weight reduction in adults with obesity or in adults with overweight who have at least one weight-related comorbid condition. (fda.gov) The FDA also described Foundayo as the first new molecular entity approved under the agency’s National Priority Voucher pilot program, with the decision issued 50 days after filing and ahead of the application’s January 20, 2027 PDUFA date. ### What kind of weight-loss results did trials show? (investor.lilly.com) Lilly said adults taking Foundayo in the ATTAIN-1 clinical trial lost an average of 27 pounds on the highest dose. A New England Journal of Medicine clinician summary published in April said two clinical trials showed weight loss averaging about 10% with orforglipron, compared with about 2% with placebo. (fda.gov) A phase 3 NEJM paper on adults with obesity without diabetes reported that investigators tested 6 mg, 12 mg and 36 mg once-daily doses against placebo over 72 weeks. The same paper said the study enrolled 3,127 patients in a multinational, randomized, double-blind trial. The Pharmacy Times framing that patients may see roughly 5% to 10% weight loss is broadly consistent with the published trial summaries, though Lilly’s own release highlighted the higher-dose average in pounds rather than that narrower percentage range. (investor.lilly.com) ### How is this different from other GLP-1 obesity drugs? (nejm.org) NEJM’s April clinician review said orforglipron is a small-molecule oral GLP-1 agonist and the second oral GLP-1 approved for obesity, alongside semaglutide. Lilly said Foundayo is the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. That company description is broader than the FDA label, but it is the marketing position Lilly used at launch. (investor.lilly.com) FDA labeling lists tablet strengths ranging from 0.8 mg to 17.2 mg and carries a boxed warning tied to thyroid C-cell tumors, including contraindications for patients with a personal or family history of medullary thyroid carcinoma or with MEN 2. ### What do the heart-benefit reports say about GLP-1 drugs more broadly? (investor.lilly.com) ScienceDaily reported on May 21 that an international review found GLP-1 drugs significantly reduced long-term risks of heart attack, stroke, heart failure and premature death. The report was about the drug class broadly, not specifically a new cardiovascular-outcomes claim for orforglipron. (accessdata.fda.gov) That distinction matters because Foundayo’s approval documents focus on obesity treatment and weight reduction. The FDA materials surfaced here do not state a separate cardiovascular-risk-reduction indication for orforglipron. ### When did patients start getting access? April 6 was the date Lilly said shipping would begin after prescriptions were accepted immediately through LillyDirect. (sciencedaily.com) On April 9, Lilly said Foundayo was available via LillyDirect and telehealth providers and was shipping to retail pharmacies nationwide, with pricing starting at $25 per month for eligible commercially insured patients and $149 per month for self-pay. (accessdata.fda.gov) Lilly’s patient and prescriber sites now list Foundayo as approved for long-term weight management in adults meeting the labeled criteria. The next public milestones are likely to come through prescribing uptake, coverage decisions and any future label updates posted through FDA and Lilly channels. (foundayo.lilly.com) (investor.lilly.com)